ramucirumab

Org: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Division of Hepato-Gastroenterology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan,

Clinical trial

A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Status: Completed, Estimated PCD: 2021-02-22

Abstract

Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.

Org: Klinikum Rechts der Isar, Technische Universität München (TUM), Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,

Abstract

Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).

Org: Charité University Medicine Berlin, Department of Haematology, Lille University Hospital, Oncology and Cancer Immunology (CCM), Campus Virchow-Klinikum, Hematology Oncology Practice Eppendorf and University Cancer Center Hamburg (UCCH),

Abstract

Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.

Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,

Abstract

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06).

Org: Soonchunhyang University Bucheon Hospital, Pusan National University Yangsan Hospital, Ulsan University Hospital, College of Medicine, Chungbuk National University, Seoul St. Mary's Hospital,

Abstract

Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.

Org: Virginia Cancer Specialists, US Oncology Network, Mirati Therapeutics, Ontada,

Abstract

Clinical outcomes of chemotherapy rechallenge in patients with metastatic non-small cell lung (NSCLC) who progressed on immunotherapy maintenance after front line platinum doublets and immunotherapy.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center,

Abstract

Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).

Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,

Abstract

Efficacy and safety of second-line treatment for advanced gastric cancer: A network meta-analysis of randomized controlled trials.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

Real-world experience with atezolizumab plus bevacizumab in the management of non-resectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.

Org: Feist-Weiller Cancer Center at LSUHSC-Shreveport, LSU Health Shreveport, Ochsner LSU Health, Merit health, LSUHSC-S,

Abstract

Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO.

Org: Klinikum rechts der Isar, Technische Universität München, Klinik für Innere Medizin III, Munich, Germany, Munich, Germany, Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt Am Main, Germany, Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, Städtisches Klinikum Dresden, IV. Medical Clinic, Dresden, Germany, CaritasKlinikum Saarbrücken, Klinik für Hämatologie und Onkologie, Saarbrücken, Germany,

Abstract

Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.

Org: Mayo Clinic Florida, Mayo Clinic,

Abstract

A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC).

Org: University of Michigan, University of Michigan, Rogel Cancer Center, Henry Ford Cancer Institute, Detroit, MI, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, University of Michigan Health System Comprehensive Cancer Center,

Abstract

Risk factors and early biomarkers of nephrotoxicity associated with the use of anti‑VEGF drugs.

Org: SBIH "Tver Regional Clinical Oncology Center", Tver, Russian Federation, Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM, Lomonosow Moscow State University,

Abstract

Outcomes of stage IV non-small cell lung cancer patients after failure of platinum-based chemotherapy in clinical trials and real-world settings: A literature review.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute Singapore, Real Chemistry, Inc., Novocure Inc., NovoCure,

Abstract

Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy.

Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Jacksonville, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20266